Genflow Biosciences PLC Final Results
07 Maggio 2024 - 8:00AM
RNS Regulatory News
RNS Number : 2472N
Genflow Biosciences PLC
07 May 2024
THE
INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE
COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE
MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK
DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018,
AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A
REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO
BE IN THE PUBLIC DOMAIN.
7 May 2024
Genflow Biosciences
Plc
("Genflow" or "the Company")
FINAL
RESULTS
Genflow Biosciences Plc (LSE:GENF)
(OTCQB:GENFF) ("Genflow" or "the Company"), an emerging leader in
the field of longevity research, focused on developing therapeutic
solutions for the prevention of age-related diseases, is
pleased to announce its final results for the year
ended 31 December 2023. The Annual Report is available to view on
the Company's website at www.genflowbio.com
The Company will post the Annual
Report to shareholders and provide notice for its Annual General
Meeting in the coming weeks.
Genflow is a
UK-based biotechnology company focused on longevity and the
development of therapies to counteract the effects of aging and
diseases associated with advanced age. It is the first
longevity biotechnology company to list in Europe and seeks to be a
reference company in the European longevity sector.
Contacts
|
Genflow Biosciences
|
Harbor Access
|
|
Dr Eric Leire, CEO
|
Jonathan Paterson, Investor
Relations
|
|
+32-477-495-881
|
+1 475 477 9401
|
|
|
Jonathan.Paterson@Harbor-access.com
|
|
|
|
|
Joint Corporate Brokers
|
|
|
Clear Capital Markets
|
Capital Plus Partners Ltd
|
|
Bob Roberts, +44 203 869
6080
|
Dominic Berger, +44 203 821
6167
|
|
|
Keith Swann, +44 0203 821
6169
|
|
|
Jon Critchley, +44 0203 821
6168
|
|
|
|
About Genflow Biosciences
Founded in 2020, Genflow Biosciences
Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company
headquartered in the UK with R&D facilities in Belgium, is
pioneering gene therapies to decelerate the aging process, with the
goal of promoting longer and healthier lives while mitigating the
financial, emotional, and social impacts of a fast-growing aging
global population. Genflow's lead compound, GF-1002, works through
the delivery of a centenarian variant of the SIRT6 gene which has
yielded promising preclinical results. Scheduled to begin in 2025,
Genflow's clinical trial aims to explore the potential benefits of
GF-1002 in treating non-alcoholic steatohepatitis (NASH), the most
prevalent chronic liver disease for which there is no effective
treatments. Please visit www.genflowbio.com
and follow the Company on LinkedIn and Twitter/X.
-Ends-
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
ACSQKNBNQBKDCPK
Grafico Azioni Genflow Biosciences (LSE:GENF)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Genflow Biosciences (LSE:GENF)
Storico
Da Dic 2023 a Dic 2024
